Profitability
This table compares Biotricity and Nemaura Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biotricity | -80.42% | N/A | -188.47% |
| Nemaura Medical | N/A | N/A | N/A |
Risk & Volatility
Biotricity has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.
Insider & Institutional Ownership
3.9% of Biotricity shares are owned by institutional investors. Comparatively, 4.4% of Nemaura Medical shares are owned by institutional investors. 10.1% of Biotricity shares are owned by insiders. Comparatively, 40.4% of Nemaura Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biotricity | $12.06 million | 1.00 | -$14.09 million | ($0.17) | -2.65 |
| Nemaura Medical | $3,017.00 | 1.34 | -$14.14 million | ($0.50) | 0.00 |
Biotricity has higher revenue and earnings than Nemaura Medical. Biotricity is trading at a lower price-to-earnings ratio than Nemaura Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Nemaura Medical beats Biotricity on 6 of the 10 factors compared between the two stocks.
About Biotricity
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
About Nemaura Medical
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Receive News & Ratings for Biotricity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotricity and related companies with MarketBeat.com's FREE daily email newsletter.
